Company Overview and News

 
World Financial Split Corp. Declares Quarterly Preferred Share Distribution

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- (TSX: WFS.PR.A) World Financial Split Corp. has declared a quarterly distribution on its preferred shares in the amount of $0.13125 payable on September 28, 2018 to shareholders of record on September 14, 2018. To the extent that any portions of the distributions are ordinary taxable dividends and not capital gains dividends, they will be eligible dividends.
WFS

 
World Financial Split Corp. Announces Partial Redemption of Preferred Shares

2018-06-25 globenewswire
TORONTO, June 25, 2018 (GLOBE NEWSWIRE) -- (TSX:WFS) World Financial Split Corp. (the “Fund”) will effect a partial redemption of its Preferred Shares in order to maintain an equal number of Preferred Shares and Class A Shares of the Fund outstanding in accordance with the Fund’s articles. The partial redemption of Preferred Shares is being made in connection with the automatic seven-year extension of the term of the Fund from June 30, 2018 until June 30, 2025 (the “Extension”).
WFS

 
World Financial Split Corp. Declares Quarterly Preferred Share Distribution

2018-06-04 globenewswire
TORONTO, June 04, 2018 (GLOBE NEWSWIRE) -- (TSX:WFS.PR.A) World Financial Split Corp. has declared a quarterly distribution on its preferred shares in the amount of $0.13125 payable on June 29, 2018 to shareholders of record on June 15, 2018. To the extent that any portions of the distributions are ordinary taxable dividends and not capital gains dividends, they will be eligible dividends.
WFS

 
World Financial Split Corp. Announces Automatic Term Extension

2018-05-28 globenewswire
TORONTO, May 28, 2018 (GLOBE NEWSWIRE) -- (TSX:WFS) (TSX:WFS.PR.A) World Financial Split Corp. (the “Company”) is pleased to announce that the board of directors has approved an extension of the maturity date of the Class A & Preferred Shares of the Company for an additional seven year period beyond June 30, 2018 to June 30, 2025 as provided for in its articles of incorporation.
WFS

 
World Financial Split Corp. Announces Year End Results

2018-03-23 globenewswire
TORONTO, March 23, 2018 (GLOBE NEWSWIRE) -- (TSX:WFS) (TSX:WFS.PR.A) World Financial Split Corp. (the “Fund”) announces results of operations for the year ended December 31, 2017. Increase in net assets attributable to holders of Class A shares amounted to $2.30 million or $1.10 per Class A share. As at December 31, 2017, net assets attributable to holders of Class A shares were $9.99 million or $4.
WFS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...